Mitchell Blewett, PharmD, MS, of Cleveland Clinic, explains why formulary approval is only the midpoint before a new oncology drug reaches patients.
Mitchell Blewett, PharmD, MS, BCOP, BCPS
Advertisement
Mitchell Blewett, PharmD, MS, BCOP, is the director of Oncology Pharmacy at Cleveland Clinic.
Articles by Mitchell Blewett, PharmD, MS, BCOP, BCPS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial
2
Biosimilar Entry Should Trigger a Fresh Look at Biologic Access
3
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
4
Telehealth Overtakes Travel in States With Total Abortion Bans
5